latentbrief
Back to news
General1d ago

$2.1 Billion Boost for AI Drug Discovery

The Decoder1 min brief

In brief

  • Isomorphic Labs, a leading AI-driven drug research company founded by DeepMind co-founder Demis Hassabis, has secured a significant investment of $2.1 billion in its Series B round led by Thrive Capital.
    • This funding will be utilized to expand IsoDDE, the company's proprietary AI platform, and accelerate several drug candidates into clinical trials.
    • This move underscores the growing confidence in AI's potential to revolutionize the pharmaceutical industry.
  • By automating complex drug discovery processes, IsoDDE can analyze vast datasets and identify promising compounds more efficiently than traditional methods.
  • The investment highlights the importance of scaling such technologies to address unmet medical needs and potentially bring life-saving treatments to market faster.
  • With this new capital, Isomorphic Labs aims to expand its research capabilities and collaborate with leading biotech companies.
  • Watch for updates on how AI-driven drug discovery continues to transform healthcare and deliver innovative therapies.

Terms in this brief

IsoDDE
IsoDDE is Isomorphic Labs' AI platform designed for drug discovery. It uses artificial intelligence to analyze large datasets and identify promising compounds more efficiently than traditional methods, potentially speeding up the development of life-saving treatments.

Read full story at The Decoder

More briefs